Journal article suggests heart risks with Pargluva diabetes drug

10/21/2005 | Wall Street Journal, The

Researchers who examined information from Bristol-Myers Squibb's clinical trials of its Pargluva diabetes drug recommended in the Journal of the American Medical Association the drug should undergo another trial to test it for heart safety. The researchers said the data show the drug could be linked to heart attacks, strokes and death. The FDA cited a need for such information in declining to approve the drug, despite a strong recommendation from an advisory panel. The drugmaker and Merck, the drug's co-marketer, said there are "many different and appropriate ways to analyze data."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA